Valeant Pharmaceuticals
E813059
Valeant Pharmaceuticals was a controversial multinational specialty pharmaceutical company known for aggressive drug price hikes, rapid growth through acquisitions, and subsequent accounting and regulatory scandals.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Valeant Pharmaceuticals canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9668356 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Valeant Pharmaceuticals Context triple: [Pershing Square Holdings, hasSignificantShareholderRoleIn, Valeant Pharmaceuticals]
-
A.
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company based in Israel, best known as one of the world’s largest manufacturers of generic medicines and a producer of specialty and over-the-counter drugs.
-
B.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company known for developing and manufacturing innovative medicines in areas such as oncology, immunology, and cardiovascular disease.
-
C.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
D.
Alkermes
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
E.
Merck & Co.
Merck & Co. is a major American pharmaceutical company known for developing and producing vaccines, oncology drugs, and other innovative medicines.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Valeant Pharmaceuticals Target entity description: Valeant Pharmaceuticals was a controversial multinational specialty pharmaceutical company known for aggressive drug price hikes, rapid growth through acquisitions, and subsequent accounting and regulatory scandals.
-
A.
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company based in Israel, best known as one of the world’s largest manufacturers of generic medicines and a producer of specialty and over-the-counter drugs.
-
B.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company known for developing and manufacturing innovative medicines in areas such as oncology, immunology, and cardiovascular disease.
-
C.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
D.
Alkermes
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
E.
Merck & Co.
Merck & Co. is a major American pharmaceutical company known for developing and producing vaccines, oncology drugs, and other innovative medicines.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical company
ⓘ
public company ⓘ |
| acquired |
Bausch & Lomb
NERFINISHED
ⓘ
Dendreon NERFINISHED ⓘ Medicis Pharmaceutical NERFINISHED ⓘ Salix Pharmaceuticals NERFINISHED ⓘ |
| auditor | PricewaterhouseCoopers NERFINISHED ⓘ |
| businessModel | acquisition-driven growth strategy ⓘ |
| businessPartnerOf | Valeant Pharmaceuticals NERFINISHED ⓘ |
| CEO | J. Michael Pearson NERFINISHED ⓘ |
| chairman | J. Michael Pearson NERFINISHED ⓘ |
| country | Canada ⓘ |
| criticizedFor |
complex accounting practices
ⓘ
high leverage and debt levels ⓘ raising prices of acquired drugs ⓘ |
| faced | congressional hearings in the United States ⓘ |
| formerName |
Biovail Corporation
NERFINISHED
ⓘ
Valeant Pharmaceuticals International, Inc. NERFINISHED ⓘ |
| headquartersLocation | Laval, Quebec, Canada NERFINISHED ⓘ |
| industry |
pharmaceuticals
ⓘ
specialty pharmaceuticals ⓘ |
| investedIn | Valeant Pharmaceuticals NERFINISHED ⓘ |
| investmentThrough | Pershing Square Capital Management NERFINISHED ⓘ |
| involvedIn | Philidor specialty pharmacy controversy NERFINISHED ⓘ |
| knownFor |
accounting controversies
ⓘ
aggressive drug price increases ⓘ rapid growth through acquisitions ⓘ regulatory investigations ⓘ |
| listedAs | Valeant Pharmaceuticals International, Inc. NERFINISHED ⓘ |
| majorShareholder | Bill Ackman NERFINISHED ⓘ |
| marketCapitalizationTrend | sharp decline after 2015 ⓘ |
| mergedInto | Valeant Pharmaceuticals NERFINISHED ⓘ |
| positionHeld | Chief Executive Officer of Valeant Pharmaceuticals ⓘ |
| renamedAs | Bausch Health Companies Inc. NERFINISHED ⓘ |
| reputation | highly controversial in pharmaceutical industry ⓘ |
| restated | certain financial results ⓘ |
| stockExchange |
New York Stock Exchange
ⓘ
Toronto Stock Exchange NERFINISHED ⓘ |
| subjectOf |
Canadian securities regulators investigations
ⓘ
U.S. Department of Justice investigations ⓘ U.S. Securities and Exchange Commission investigations ⓘ |
| therapyArea |
dermatology
ⓘ
gastroenterology ⓘ neurology ⓘ ophthalmology ⓘ |
| tickerSymbol | VRX NERFINISHED ⓘ |
| timePeriodOfMajorControversy | early 2010s to late 2010s ⓘ |
| usedSpecialtyPharmacy | Philidor Rx Services NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Valeant Pharmaceuticals Description of subject: Valeant Pharmaceuticals was a controversial multinational specialty pharmaceutical company known for aggressive drug price hikes, rapid growth through acquisitions, and subsequent accounting and regulatory scandals.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
Pershing Square Holdings (historical significant shareholder)
→
hasSignificantShareholderRoleIn
→
Valeant Pharmaceuticals
ⓘ
subject surface form:
Pershing Square Holdings